<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984410</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-1420-HNCG-ROG</org_study_id>
    <nct_id>NCT02984410</nct_id>
  </id_info>
  <brief_title>Study Assessing The &quot;Best of&quot; Radiotherapy vs the &quot;Best of&quot; Surgery in Patients With Oropharyngeal Carcinoma</brief_title>
  <acronym>Best Of</acronym>
  <official_title>Phase III Study Assessing the &quot;Best of&quot; Radiotherapy Compared to the &quot;Best of&quot; Surgery (Trans-oral Surgery (TOS)) in Patients With T1-T2, N0-N1 Oropharyngeal, Supraglottic Carcinoma and With T1, N0 Hypopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oropharyngeal Squamous Cell Carcinoma (OPSCC) arises in the soft palate, tonsils, base of&#xD;
      tongue, pharyngeal wall, and the vallecula. Most of the patients with early stage OPSCC are&#xD;
      usually cured. Treatment of early stage OPSCC can be successfully achieved with primary&#xD;
      surgery including neck dissection, as indicated, or with definitive radiotherapy. The current&#xD;
      standard treatment for OPSCC is therefore based on either surgery and/or radiotherapy, both&#xD;
      associated with comparable, high tumor control rates but with different side effects profiles&#xD;
      and technical constraints.&#xD;
&#xD;
      In order to decrease the potential morbidity of surgery, transoral approaches have been&#xD;
      developed within the last decades, including transoral robotic surgery (TORS), transoral&#xD;
      laser microsurgery (TLM) or conventional transoral techniques. On the other hand, patients&#xD;
      with head and neck cancer treated with IMRT experienced significant improvements in cause&#xD;
      specific survival (CSS) compared with patients treated with non-IMRT techniques thus&#xD;
      suggesting that IMRT may be beneficial in terms of patient's outcomes and toxicity profile.&#xD;
      It is as yet unclear however, which one of the new techniques is superior to the other in&#xD;
      terms of function preservation. Given that the functional outcome of most importance is&#xD;
      swallowing function, the preservation of swallowing is thus of major importance.&#xD;
&#xD;
      The main objective of the study is to assess and compare the patient-reported swallowing&#xD;
      function over the first year after randomization to either IMRT or TOS among patients with&#xD;
      early stage OPSCC, SGSCC, and HPSCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomized 1 to 1 to surgery (Arm 1) or radiotherapy (Arm 2).&#xD;
&#xD;
      ARM 1: Surgery&#xD;
&#xD;
      Trans-oral surgery (any trans-oral approach such as trans-oral laser microsurgery&#xD;
      conventional trans-oral surgery or trans-oral robotic surgery) will be applied to all&#xD;
      patients in this arm.&#xD;
&#xD;
      A surgical margin is defined to be clear (R0), if found to be &gt;/=3mm in the final specimen&#xD;
      (except deep margin for tonsillar resection, that is either R1 or R0), is defined to be&#xD;
      close, if 1-&lt;3mm, and considered to be involved (R1), if &lt;1mm in the final specimen. Clearly&#xD;
      defined marginal biopsies are required for each TOS-technique. Trans-oral re-resections are&#xD;
      required in case of R1 or close-margin to convert the patient to an R0-status.Postoperative&#xD;
      RT or chemo-RT will be given within 5-6 weeks of surgery in case of positive.&#xD;
&#xD;
      ARM 2: Radiotherapy&#xD;
&#xD;
      Intensity modulated radiation therapy (IMRT) with Simultaneous integrated boost (SIB) will be&#xD;
      applied to all patients in this arm. PTV prescription to tumor and high risk areas will be&#xD;
      delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks,&#xD;
      elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in&#xD;
      33-35 fractions of 1.55-1.65 Gy over 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the MD Anderson Dysphagia Inventory (MDADI) score</measure>
    <time_frame>at 4.5, 6, 9 and 12 months after randomization</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <condition>Supraglottic Squamous Cell Carcinoma</condition>
  <condition>Hypopharyngeal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Intensity-Modulated Radiation Therapy (IMRT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trans Oral Surgery (TOS)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The following surgical techniques are allowed:&#xD;
Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy (IMRT)</intervention_name>
    <description>IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection</description>
    <arm_group_label>Intensity-Modulated Radiation Therapy (IMRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trans Oral Surgery (TOS)</intervention_name>
    <description>TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection</description>
    <arm_group_label>Trans Oral Surgery (TOS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  OPSCC in one of the following sub-sites: base of tongue, lateral pharyngeal wall,&#xD;
             tonsil, glosso-tonsillar sulcus, vallecula or SGSCC in one or more of the following&#xD;
             sub-sites: epiglottis, aryepiglottic fold, false cord or HPSCC in one or more of the&#xD;
             following subsites: Lateral and medial wall of piriform sinus (sub-sites are defined&#xD;
             as lateral (lateral pharyngeal wall, tonsil, glosso-tonsillar sulcus, lateral piriform&#xD;
             sinus) vs. central lesions (base of tongue, vallecula, all supraglottic sites, medial&#xD;
             wall of piriform sinus))&#xD;
&#xD;
          -  TNM stage I-III (7th AJCC classification): T1 or T2, N0 or T1 or T2, N1 with one&#xD;
             single neck node ≤ 3cm without radiographic signs of extracapsular extension (ECE),&#xD;
             M0;&#xD;
&#xD;
          -  TNM stage I for HPSCC: T1, N0, M0. ;&#xD;
&#xD;
          -  Within 2 weeks before randomization, assessment by a Multi-Disciplinary Team (MDT)&#xD;
             composed of at least a head and neck/ENT surgeon, oncologist, radiologist,&#xD;
             radiotherapist, and pathologist of the treatment naïve patient and suitable for either&#xD;
             TOS or IMRT based on:&#xD;
&#xD;
          -  CT with contrast and/or MRI done within 4 weeks prior to randomization Note: Repeat&#xD;
             contrast enhanced CT and/or MRI or US 1 week or less prior to randomization in case of&#xD;
             suspicious nodes &lt;1cm on initial scan if per local practice&#xD;
&#xD;
          -  Pan-endoscopy with assessment of trans-oral exposure for resection.&#xD;
&#xD;
          -  peri-nodal infiltration either via CT-scan or MRI.&#xD;
&#xD;
          -  Age 18 and older; Age 18 to 70 for SGSCC&#xD;
&#xD;
          -  ECOG Performance status ≤ 2;&#xD;
&#xD;
          -  Availability of biological material for HPV/p16 testing for OPSCCs&#xD;
&#xD;
          -  Study information and Informed consent discussed by the surgeon and radio-oncologist&#xD;
             and signed by the patient.&#xD;
&#xD;
          -  Within 2 weeks prior randomization:&#xD;
&#xD;
          -  Baseline MDADI score available;&#xD;
&#xD;
          -  Adequate bone marrow function as demonstrated by neutrophils count &gt; 1,5 109 /L ,&#xD;
             platelets count &gt; 75 109 /L, WBC≥ 3.0 109 /L;&#xD;
&#xD;
          -  Prothrombin time (PT) with an international normalized ratio (INR) ≤ 1.2&#xD;
&#xD;
          -  Partial thromboplastin time (PTT) ≤ 1.2 times ULN&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test no more than 72 hours prior to randomization.&#xD;
&#xD;
          -  Patients of childbearing / reproductive potential should agree to use adequate birth&#xD;
             control measures for 3 months, especially if they will undergo any radiotherapy&#xD;
             treatment at any time during the study. A highly effective method of birth control is&#xD;
             defined as those which result in low failure rate (i.e. less than 1% per year) when&#xD;
             used consistently and correctly.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Any previous anti-cancer therapy for HNSCC (surgery, chemo-, or radiotherapy or&#xD;
             molecular targeted therapy);&#xD;
&#xD;
          -  Any active malignancy (other than non-melanoma skin cancer or localized cervical&#xD;
             cancer or localized and presumed cured prostatic cancer) within the last 5 years with&#xD;
             ongoing systemic treatment&#xD;
&#xD;
          -  Cancer in contact with the internal and/or common carotid artery&#xD;
&#xD;
          -  Extension of OPSCC across the midline of the base-of-tongue&#xD;
&#xD;
          -  Arytenoid involvement in case of SGSCC&#xD;
&#xD;
          -  Infiltration of apex for piriform sinus in case of HPSCC&#xD;
&#xD;
          -  Cancer originating from the soft palate or posterior pharyngeal wall&#xD;
&#xD;
          -  Requirement of a reconstruction with a free or regional flap (i.e. involvement of &gt;50%&#xD;
             of the soft palate)&#xD;
&#xD;
          -  Pre-existing dysphagia not related to the oropharyngeal cancer or diagnostic biopsies&#xD;
&#xD;
          -  Any psychological, cognitive, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol, completion of patient&#xD;
             reported measures and follow-up schedule; those conditions should be discussed with&#xD;
             the patient before registration in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Simon</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EORTC HQ</last_name>
    <phone>+32 2 774 16 11</phone>
    <email>eortc@eortc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet-Hopital Universitaire ULB</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>U.Z. Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg - Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaets Krankenhaus Eppendorf - UKE - University Cancer Center</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Leipzig - Klinikum St Georg</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen- Crona Kliniken</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm-Michelsberg-HNO</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Great Poland Cancer Centre</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central De Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois - Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zurich - Klinik fur Ohren, Hals und Gesichtschirurgie</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital NHS - Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale University Health Board - University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust - Castle Hill Hospital</name>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust - Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1-T2, N0-N1 oropharyngeal carcinoma, supraglottic carcinoma, T1, N0 hypopharyngeal carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

